Does the media favor ANTX or AMPH?

In the previous week, Anthem had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Anthem and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.19 beat Anthem's score of 0.88 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TBPH or ANTX?

In the previous week, Anthem had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Anthem and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.96 beat Anthem's score of 0.88 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ANTX or SGP?

Anthem is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is ANTX or SGP more profitable?

Anthem's return on equity of -53.52% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Spyglass Pharma N/A -62.40% -24.83%

Which has stronger earnings and valuation, HELP or ANTX?

Anthem is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Anthem N/A N/A -$35.17M -$1.07 N/A

Is HELP or ANTX more profitable?

Anthem's return on equity of -53.52% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Anthem N/A -53.52% -48.63%

Does the media prefer HELP or ANTX?

In the previous week, Cybin had 21 more articles in the media than Anthem. MarketBeat recorded 25 mentions for Cybin and 4 mentions for Anthem. Anthem's average media sentiment score of 0.88 beat Cybin's score of 0.54 indicating that Anthem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anthem (ANTX) Competitors

$5.71 +0.05 (+0.88%)

As of 02:26 PM Eastern

Compare

ANTX vs. AMPH, TBPH, SGP, ESPR, and HELP

Should you buy Anthem stock or one of its competitors? Anthem's main competitors and comparable companies include Amphastar Pharmaceuticals (AMPH), Theravance Biopharma (TBPH), Spyglass Pharma (SGP), Esperion Therapeutics (ESPR), and Cybin (HELP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Anthem compare to Amphastar Pharmaceuticals?

Anthem (NASDAQ:ANTX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Amphastar Pharmaceuticals has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Amphastar Pharmaceuticals	$719.89M	1.30	$98.09M	$1.69	13.04

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Anthem's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

In the previous week, Anthem had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Anthem and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.19 beat Anthem's score of 0.88 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anthem has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Anthem currently has a consensus price target of $9.00, indicating a potential upside of 55.98%. Amphastar Pharmaceuticals has a consensus price target of $22.50, indicating a potential upside of 2.09%. Given Anthem's stronger consensus rating and higher possible upside, equities research analysts plainly believe Anthem is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

90.5% of Anthem shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 22.6% of Anthem shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Amphastar Pharmaceuticals beats Anthem on 10 of the 15 factors compared between the two stocks.

How does Anthem compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Anthem had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Anthem and 3 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.96 beat Anthem's score of 0.88 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Theravance Biopharma currently has a consensus target price of $19.40, suggesting a potential upside of 13.85%. Anthem has a consensus target price of $9.00, suggesting a potential upside of 55.98%. Given Anthem's stronger consensus rating and higher probable upside, analysts clearly believe Anthem is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Theravance Biopharma has a net margin of 51.58% compared to Anthem's net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Anthem	N/A	-53.52%	-48.63%

Theravance Biopharma has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.87
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by insiders. Comparatively, 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Anthem has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

Summary

Theravance Biopharma beats Anthem on 11 of the 16 factors compared between the two stocks.

How does Anthem compare to Spyglass Pharma?

Anthem (NASDAQ:ANTX) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

90.5% of Anthem shares are owned by institutional investors. 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anthem's return on equity of -53.52% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Spyglass Pharma	N/A	-62.40%	-24.83%

Anthem is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

In the previous week, Anthem had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 4 mentions for Anthem and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Anthem's score of 0.88 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Anthem	Positive
Spyglass Pharma	Very Positive

Anthem currently has a consensus price target of $9.00, indicating a potential upside of 55.98%. Spyglass Pharma has a consensus price target of $44.00, indicating a potential upside of 69.04%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Anthem and Spyglass Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Anthem compare to Esperion Therapeutics?

Anthem (NASDAQ:ANTX) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Esperion Therapeutics has higher revenue and earnings than Anthem. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

In the previous week, Anthem had 4 more articles in the media than Esperion Therapeutics. MarketBeat recorded 4 mentions for Anthem and 0 mentions for Esperion Therapeutics. Anthem's average media sentiment score of 0.88 beat Esperion Therapeutics' score of 0.00 indicating that Anthem is being referred to more favorably in the media.

Company	Overall Sentiment
Anthem	Positive
Esperion Therapeutics	Neutral

Esperion Therapeutics has a net margin of 0.12% compared to Anthem's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Esperion Therapeutics	0.12%	-0.14%	0.12%

90.5% of Anthem shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 22.6% of Anthem shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Anthem has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Anthem presently has a consensus target price of $9.00, suggesting a potential upside of 55.98%. Esperion Therapeutics has a consensus target price of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Esperion Therapeutics beats Anthem on 8 of the 15 factors compared between the two stocks.

How does Anthem compare to Cybin?

Cybin (NASDAQ:HELP) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Cybin currently has a consensus price target of $48.60, indicating a potential upside of 251.41%. Anthem has a consensus price target of $9.00, indicating a potential upside of 55.98%. Given Cybin's stronger consensus rating and higher probable upside, research analysts clearly believe Cybin is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cybin had 21 more articles in the media than Anthem. MarketBeat recorded 25 mentions for Cybin and 4 mentions for Anthem. Anthem's average media sentiment score of 0.88 beat Cybin's score of 0.54 indicating that Anthem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.9% of Cybin shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cybin has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Anthem has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market.

Anthem is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

Anthem's return on equity of -53.52% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Anthem	N/A	-53.52%	-48.63%

Summary

Anthem beats Cybin on 7 of the 13 factors compared between the two stocks.

Get Anthem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANTX vs. The Competition

Export

Metric	Anthem	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$217.76M	$12.41B	$7.30B	$12.76B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	-5.39	783.02	272.80	24.16
Price / Sales	N/A	761.13	626.81	98.22
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	2.87	12.03	13.14	6.23
Net Income	-$35.17M	$2.83B	$3.47B	$348.07M
7 Day Performance	-3.19%	1.92%	1.22%	0.63%
1 Month Performance	17.28%	6.14%	8.61%	4.81%
1 Year Performance	417.49%	8.13%	26.08%	16.86%

Anthem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANTX Anthem	2.3914 of 5 stars	$5.71 +0.9%	$9.00 +57.6%	+403.6%	$215.50M	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	2.3598 of 5 stars	$20.87 +3.4%	$22.00 +5.4%	-26.3%	$887.64M	$719.89M	12.35	1,976	Positive News
TBPH Theravance Biopharma	3.5575 of 5 stars	$16.96 +0.2%	$19.40 +14.4%	+23.4%	$880.29M	$104.31M	16.79	110	Short Interest Decrease
SGP Spyglass Pharma	2.7732 of 5 stars	$26.17 +4.0%	$44.00 +68.2%	N/A	$874.70M	N/A	N/A	65	Positive News
ESPR Esperion Therapeutics	N/A	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANTX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anthem (ANTX) Competitors

ANTX vs. AMPH, TBPH, SGP, ESPR, and HELP

How does Anthem compare to Amphastar Pharmaceuticals?

Summary

How does Anthem compare to Theravance Biopharma?

Summary

How does Anthem compare to Spyglass Pharma?

Summary

How does Anthem compare to Esperion Therapeutics?

Summary

How does Anthem compare to Cybin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anthem (ANTX) Competitors

ANTX vs. AMPH, TBPH, SGP, ESPR, and HELP

How does Anthem compare to Amphastar Pharmaceuticals?

Which has better earnings & valuation, ANTX or AMPH?

Is ANTX or AMPH more profitable?

Does the media favor ANTX or AMPH?

Which has more volatility & risk, ANTX or AMPH?

Do analysts rate ANTX or AMPH?

Do institutionals and insiders have more ownership in ANTX or AMPH?

Summary

How does Anthem compare to Theravance Biopharma?

Does the media refer more to TBPH or ANTX?

Do analysts prefer TBPH or ANTX?

Is TBPH or ANTX more profitable?

Which has better valuation and earnings, TBPH or ANTX?

Do institutionals and insiders hold more shares of TBPH or ANTX?

Which has more risk and volatility, TBPH or ANTX?

Summary

How does Anthem compare to Spyglass Pharma?

Do insiders & institutionals have more ownership in ANTX or SGP?

Is ANTX or SGP more profitable?

Which has higher earnings and valuation, ANTX or SGP?

Does the media refer more to ANTX or SGP?

Do analysts rate ANTX or SGP?

Summary

How does Anthem compare to Esperion Therapeutics?

Which has higher valuation & earnings, ANTX or ESPR?

Does the media favor ANTX or ESPR?

Is ANTX or ESPR more profitable?

Do insiders and institutionals have more ownership in ANTX or ESPR?

Which has more volatility & risk, ANTX or ESPR?

Do analysts prefer ANTX or ESPR?

Summary

How does Anthem compare to Cybin?

Do analysts recommend HELP or ANTX?

Does the media prefer HELP or ANTX?

Do institutionals & insiders believe in HELP or ANTX?

Which has more risk & volatility, HELP or ANTX?

Which has stronger earnings and valuation, HELP or ANTX?

Is HELP or ANTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools